Correlation Between Mineralys Therapeutics, and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Molecular Partners AG, you can compare the effects of market volatilities on Mineralys Therapeutics, and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Molecular Partners.

Diversification Opportunities for Mineralys Therapeutics, and Molecular Partners

0.23

Correlation Coefficient

Mineralys Therapeutics,  Molecular Partners

Modest diversification

The 3 months correlation between Mineralys and Molecular is 0.23. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Molecular Partners go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Molecular Partners

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.82 times more return on investment than Molecular Partners. However, Mineralys Therapeutics, Common is 1.23 times less risky than Molecular Partners. It trades about -0.03 of its potential returns per unit of risk. Molecular Partners AG is currently generating about -0.04 per unit of risk. If you would invest  1,446  in Mineralys Therapeutics, Common on May 6, 2025 and sell it today you would lose (104.00) from holding Mineralys Therapeutics, Common or give up 7.19% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Molecular Partners AG

Mineralys Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics, is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's essential indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Mineralys Therapeutics, and Molecular Partners

The main advantage of trading using opposite Mineralys Therapeutics, and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Mineralys Therapeutics, Common and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.